Press releases

Date		Headline
26/07/10		Oxford BioMedica Announces FDA Approval for TroVax^® Phase II Study in Prostate Cancer
01/07/10		Oxford BioMedica Plc - Research and Development Day
01/07/10		Oxford BioMedica and VIB-K.U.Leuven Announce Collaborative Research Project Funded by The Motor Neurone Disease Association to Develop MoNuDin for Treatment of Amyotrophic Lateral Sclerosis
24/06/10		Oxford BioMedica Announces Collaborative Phase I/II Study to Evaluate TroVax in Mesothelioma
18/06/10		Oxford BioMedica Announces Amendment to 5T4 Licence Agreement with Cancer Research Technology and Issue of Shares
14/06/10		Oxford BioMedica Announces Two-year Phase I/II Results of ProSavin^® In Parkinson's Disease
19/05/10		Oxford BioMedica Plc Interim Management Statement
27/04/10		Oxford BioMedica Plc Annual General Meeting
21/04/10		Oxford BioMedica Plc Board Change
10/03/10		Oxford BioMedica Plc: Preliminary Results for the Year Ended 31 December 2009
17/02/10		Oxford BioMedica: Notice of FY2009 Preliminary Results
27/01/10		Oxford BioMedica and ALS Therapy Development Institute Extend Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
27/01/10		Oxford BioMedica and Bavarian Nordic Announce Settlement of MVA-BN^® Litigation and Cross License of Patents
22/01/10		Oxford BioMedica Secures Exclusive License for Key Intellectual Property Related to Ocular Products
20/01/10		Oxford BioMedicas UshStat For Usher Syndrome Receives European Orphan Drug Designation
05/01/10		Oxford BioMedica Plc Management and Board Changes